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Abstract—The ototoxic damage that drugs such as neomycin, kanamycin, colistin, cisplatin, transplatin
and carboplatin cause on outer and inner hair cells in postnatal day 3 rat cochlear explants was investi-
gated. Phalloidin–fluorescein conjugate-stained stereocilia bundles of sensory hair cells were quantified
by video image analysis as a measurement of ototoxic eect. The video image quantification system
established dose–response curves for ototoxic drugs (e.g. calculation of an IC50) and allowed compari-
sons between several ototoxins from the same family. This methodology provided the means to assess
the ecacy of otoprotectant agents in preventing ototoxicity. Poly-l-aspartate (10ÿ5 M) and poly-l-gluta-
mate (10ÿ5 M) protected auditory hair cells from neomycin (10ÿ3 M) toxicity while reduced glutathione
(10ÿ3 M) provided protection against cisplatin (10ÿ4 M)-induced hair cell damage. # 1998 Published by
Elsevier Science Ltd. All rights reserved
Keywords: cochlea; aminoglycosides; cisplatin; ototoxicity; otoprotection.
Abbreviations: DMEM=Dulbecco’s modified Eagle’s medium; GSH= reduced glutathione;
IHC = inner hair cells; OHC= outer hair cells; PBS = phosphate buered saline.
INTRODUCTION
Hearing loss and impairment of balance are classi-
cal side-eects of important classes of therapeutic
agents, for example, antibiotics of the aminoglyco-
side family and anticancer agents such as platin de-
rivatives (Chiodo and Alberti, 1994; Harpur, 1981).
The primary targets of these drugs in the inner ear
are the sensory hair cells of hearing and balance,
but the molecular mechanisms that lead to hair cell
death remain poorly understood.
Assessment of toxicity is a major concern in the
pharmaceutical field, and the development of in
vitro systems that can rapidly screen for toxicity
could help to avoid long, expensive in vivo studies.
Therefore, the first goal of the present study is to
establish an in vitro semi-automatic system for the
quantification of ototoxic damage that would allow
rapid screening of the auditory hair cells toxicity of
new drugs or of new derivatives of known ototoxic
drugs, in order to select new compounds and de-
rivatives that have the best therapeutic eect/tox-
icity ratios. As ototoxic compounds may have
dierent biochemical mechanisms of toxicity, we
surmized that the number of hair cells would be a
good common parameter for the evaluation of tox-
icity. Pattern recognition of the inner and outer
hair cell stereocilia allows for the counting of these
two types of auditory hair cells. Hair cell stereocilia
and cuticular plates are known to be rich in F-actin
filaments that can be labelled with phalloidin–
FITC, thereby allowing visualization of the normal
pattern of stereocilia bundles of both the inner and
outer hair cells, since there is no specific marker for
hair cells.
One approach to minimize the functional conse-
quences of ototoxic side-eects is to prevent oto-
toxic damage by co-administration of substances
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that decrease or suppress the drug’s ototoxicity
without interfering with their therapeutic eect.
In order to validate our in vitro model, we have
quantified the eects of several well-known ototoxic
drugs: (1) antibacterial aminoglycosides (neomycin,
kanamycin); (2) polypeptide antibiotics (colistin);
and (3) antineoplastic drugs (cisplatin, carboplatin,
transplatin) (Gandara et al., 1991; Koegel, 1985;
Wersa¨ll, 1995). In a second part, we have investi-
gated the applicability of our system as a tool to
screen for otoprotective agents. We have chosen the
most ototoxic aminoglycoside and antineoplastic
drugs, respectively neomycin and cisplatin, in order
to evaluate the ecacy of potential protective
agents in the in vitro model.
Besides hair cells toxicity, aminoglycosides anti-
biotics are known to be highly nephrotoxic agents
by inducing death of kidney proximal tubule epi-
thelial cells (Morin et al., 1980; Tulkens, 1989).
Several studies in rats have shown that poly-l-aspar-
tic acid, a polyanionic agent, prevents or suppresses
the nephrotoxic eects of aminoglycosides without
decreasing their antibiotic eectiveness (Williams
and Hottendorf, 1985; Williams et al., 1986). We
have therefore chosen to determine whether the
reported prevention of nephrotoxicity could be
eective in protecting the hair cells of the inner ear
from ototoxic damage.
Reduced glutathione (GSH) has been shown to
prevent the toxic peripheral neuropathy induced by
cisplatin, both in experimental animals (Cavaletti
et al., 1994; Hamers et al., 1993; Tredici et al.,
1994) and in humans (Cascinu et al., 1995).
Therefore we also have assayed for an eect of
GSH on cisplatin ototoxicity in vitro.
MATERIALS AND METHODS
Culture of explants containing the organ of Corti and
the spiral ganglion
3-Day-old Wistar rats were killed by cervical
transection, their bullae exposed and the temporal
bones removed and transferred into a glass petri
dish containing Dulbecco’s phosphate buered
saline (PBS). Using watchmaker forceps, cochleae
were dissected with the aid of a stereomicroscope.
After opening the bony capsule, the cochlear duct
was removed as a single piece together with its
band of spiral neurons. Explants were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with glucose (final concentration 6 g/
litre), the N1 cocktail (Bottenstein and Sato, 1979)
and 10% of foetal bovine serum (DMEM-FBS)
into wells of a 96-well microculture plate (Nunc).
Each explant of Corti’s organ was cultured in sus-
pension in individual wells containing 100 ml med-
ium. The cultures were kept at 378C in a humidified
atmosphere of 95% air and 5% CO2. For toxicity
screening, the medium was removed after an initial
period of 24 hr of culture and, after two rinses with
DMEM to remove the serum, replaced with 100 ml
DMEM containing an appropriate concentration of
the test drug for 48 hr, while control explants
received only DMEM. For the screening of otopro-
tective substances, the explants were first cultured
in the presence of the potential otoprotective agent
for an initial 24-hr period. The medium was then
removed, and replaced by medium containing both
the ototoxic drug and the potential otoprotectant
for an additional 48 hr of culture. At the end of
each experiment, the explant specimens were fixed
and stained for F-actin.
Tested substances
The toxicity of well known cochleotoxic drugs
such as neomycin, kanamycin, colistin, cisplatin,
carboplatin and transplatin were tested at concen-
trations ranging from 10ÿ3 to 10ÿ6 M (five concen-
trations at least per tested drug). Chloramphenicol,
a non-ototoxic antibiotic was used as a control. The
potential otoprotective agents tested were poly-l-
aspartate (mol. wt 5000–15,000), poly-l-glutamate
(mol. wt 2000–15,000) and poly-l-ornithine (mol. wt
5000–15,000) for neomycin and GSH for cisplatin.
Histochemical determination of F-actin
Explants were fixed with paraformaldehyde 4%
at room temperature for 30 min and then incubated
in PBS-Triton X100 1% for 15 min. The fixed-per-
meabilized cultures were subsequently exposed to
phalloidin–FITC (1:60) for 45 min at room tem-
perature. After 45 min, the explants were washed
twice in PBS and mounted on glass slides with non-
fading PBS/glycerol. In order to avoid variations
due to base to apex gradients of susceptibility to
ototoxic compounds (Harpur, 1987), only midpor-
tions of the phalloidin FITC-stained explants corre-
sponding to the midturn were selected.
Immunostained stereocilia bundles were observed
using a Bio-Rad MRC-1000 confocal system
coupled to a Zeiss Axiovert microscope.
Quantification of ototoxicity
The number of hair cells was determined by
video imaging using an IBAS-2000 image analysis
system (Kontron). Confocal files were transfered to
the image analysis software. The first step increased
the image contrast by first superimposing it 200-
fold and, secondly, ‘‘normalized’’ it by scaling the
actual grey levels linearly into the full dynamic
range of the image memory. In a second step, a
threshold level of grey shading was established in
order to detect all of the hair cell stereocilia bun-
dles. A threshold low enough to detect all stereoci-
lia bundles must be used, otherwise part of them
will be lost during data acquisition and subsequent
analysis. After this step, each object that was under
threshold was in black and every object that was
above threshold was in white thus allowing visual-
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ization of a digitized microscopic image. The back-
ground of cell debris or particulate matter was
eliminated from the image by grey-level erosion.
Every object was assigned its own object label for
necessary identification before counting. Computer-
recognized immunostained stereocilia bundles were
projected in colour over the original digitized
microscopic image in order to compare the pro-
cessed data with the original image. The length of
the preparation was measured and the results were
expressed in number of hair cell stereocilia bundles
per millimetre of Corti’s organ. For each condition,
four adjacent fields selected from the midportion of
each explant were analysed blindly for three
explants representing each condition (total number
of fields = 12). This program also allows dieren-
tial counting of outer (OHC) and inner hair cells
(IHC) by manual separation in the stored digitized
image of the three rows of outer hair cells from the
row of inner hair cells. Statistical analysis was
undertaken using a standard Student’s t-test.
Products and reagents
DMEM and FCS were obtained from Gibco
(Gent, Belgium). In all experiments, DMEM was
supplemented with the N1 cocktail (bovine insulin
5 mg/ml, progesterone 10ÿ8 M, putrescine 100 mM,
transferrin 100 mg/ml and selenium 310ÿ8 M) and
the glucose concentration was increased to 6 g/litre.
All reagents used were of analytical grade and were
purchased from Sigma.
RESULTS
Image analysis of organ of Corti explants after phal-
loidin–FITC staining
It is well established that the mammalian organ of
Corti is equipped with three rows of OHCs and a
single row of IHCs and provided that each row has
the same number of cells, quantitative data obtained
from stereocilia bundles counts of normal organ of
Corti explants should be composed of 75% OHCs
and 25% IHCs. This is shown in Table 1, in which
the number of OHCs and IHCs is expressed per unit
length of Corti’s organ for four dierent control
samples and, as predicted, OHCs are about three
times more numerous per unit length than IHCs,
thus validating our procedure of image analysis.
Quantification of hair cell toxicity of aminoglycosides
and platin derivatives
Plate 1 illustrates morphological aspects of phal-
loidin–FITC-stained mid-portions of organ of Corti
explants in six dierent conditions: neomycin
(10ÿ3 M, Plate 1A), kanamycin (5 10ÿ2 M, Plate
1B), colistin (10ÿ4 M, Plate 1C), cisplatin (10ÿ3 M,
Plate 1D) and carboplatin (10ÿ4 M, Plate 1E).
Chloramphenicol (10ÿ3 M), a non-ototoxic antibiotic,
was used as negative control (Plate 1F). As can be
see in photomicrographs A,B,C, D and E of Plate 1,
it is dicult to identify OHC and IHC in the treated
cultures because of the disorganizing eect that these
agents have on stereocilia bundle integrity. We have
therefore established dose–response curves by con-
sidering only the total number of auditory hair cells
per unit length. These curves have allowed the calcu-
lation of an IC50 which corresponds to the concen-
tration of the test drug at which 50% of the hair cells
are no longer detectable by phalloidin–FITC stain-
ing (Table 2). In the analysis of ototoxic eects, it
has been observed that equimolar concentrations of
kanamycin are less toxic than neomycin, which fits
with clinical data that show a greater ototoxicity for
neomycin in clinical subjects (Harpur, 1989).
Similarly, equimolar concentrations of carboplatin
have been found to be less toxic to auditory hair cells
when compared with cisplatin. These observations
also agree with clinical observations (Saito et al.,
1989; Schweitzer et al., 1986; Taudy et al., 1992).
Protective eect of poly-l-glutamic and poly-l-aspar-
tic acid against neomycin toxicity
Poly-l-ornithine (a polycationic agent) was used
as a control for the investigation of the protective
Table 2. IC50* of various pharmacologicals agents








*The IC50 represents the drug concentration at
which there is a 50% decrease in the total number
of hair cells as measured by video image analysis.
Table 1. Number of inner and outer hair cells in untreated organ of Corti explants as determined by video image analysis of phalloidin–
FITC stained stereocilia bundles
Field Length of explant (mm) No. of IHC (mm) No. of OHC (mm) IHC (%) OHC (%)
1 229.3 100 331 23 77
2 225.9 93 328 22 78
3 210.1 119 357 25 75
4 256.3 94 332 22 78




Each field represents the quantification of auditory hair cells in the middle part of an individual explant, n = 4.
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eect of poly-l-aspartate and poly-l-glutamate
(polyanionic agents). The protective eect on hair
cell survival measured by quantification of hair cells
bundles of both poly-l-aspartate and poly-l-gluta-
mate is presented in Plate 2 and Table 3. A control
explant is illustrated in Plate 2A and poly-l-aspar-
tate and poly-l-glutamate exposed cultures had a
similar appearance. The protective agents have no
eect on hair cells morphology. No protection
against the ototoxic eect of neomycin was
obtained using poly-l-ornithine. Both polyanionic
drugs, poly-l-aspartate and poly-l-glutamate, protect
against neomycin-induced hair cell toxicity at the
highest tested concentration, namely 10ÿ3 M.
Protective eect of GSH against cisplatin toxicity
The number of cisplatin-damaged hair cells is sig-
nificantly reduced in the presence of GSH (Plate 3),
thus demonstrating a protective eect of GSH on cis-
platin-induced hair cell damage. GSH alone has no
eect on hair cell morphology or number (Plate 3A).
Quantitative analysis of the protective eect of GSH
is presented in Table 4, and shows that
10ÿ3 M GSH had a significant protective eect up to
a 10ÿ4 M concentration of cisplatin but fails to pro-
tect at the 10ÿ3 M level of drug concentration. No
protection was obtained using GSH (10ÿ3 M) and
neomycin (10ÿ3–10ÿ4 M), showing that the mechan-
ism of GSH otoprotection appears to be selective.
DISCUSSION
Auditory hair cells have been well established as
the primary targets of various ototoxic agents, par-
ticularly with aminoglycosides antibiotics and anti-
cancer platin derivatives (Kroese and Van den
Bercken, 1980; Taudy et al., 1992). Their death in
the organ of Corti results in sensory deafness which,
in humans, is irreversible. Loss of hearing threshold
due to ototoxic poisoning of auditory hair cells in
birds has been shown to be transient. Indeed, in
avians, the damaged inner ear has been shown to
self-repair through the process of hair cell regener-
ation (Ryals and Rubel, 1988). As the induction of
hair cell regeneration appears to be far away from
clinical application in humans and since some oto-
toxic drugs still have to be administrated to the
patient for life-threatening diseases, an otoprotection
strategy should be developed in order to prevent
damage to the inner ear. Such an approach has
already been proposed, and the use of various mol-
ecules, such as radioprotectant (Pierson and Moller,
1981), thyroid hormone (Hangfu et al., 1992) or
high calcium concentrations (Takada and Schacht,
1982), has been shown to be eective in protecting
the inner ear from specific insults that result in hair
cell degeneration. However, to achieve the goal of
protecting hair cells from injury, we need to develop
a reliable and fast model to screen potential ototoxic
and otoprotective drugs. For this purpose, in vitro
models appear to be suitable (Kotecha and
Richardson, 1994; Richardson and Russell, 1991)
and are currently used in our laboratory (Lefebvre
et al., 1989, 1990, 1993). The semi-automatic method
of quantification using a video image analysis system
presented in this paper allows rapid and objective
quantification of the number of hair cells/mm of
Corti’s organ in organotypic explants. Using this
technique, we have established dose–response curves
and calculated IC50s, which allow comparisons
between dierent drugs (see Table 2). This screening
for ototoxic eects can potentially be extended to
any existing or newly synthesized molecules with
dierent mechanisms of ototoxicity. However, it is
important to emphasize the limitations of our
model, which are: (1) our method does not in the
strict sense quantify hair cell death, but rather hair
cell injury as demonstrated after phalloidin–FITC
staining; (2) this in vitro model cannot explain or
study the toxicologic molecular mechanism of the
drugs; and (3) this in vitro system cannot reproduce
the in vivo accumulation of ototoxic drugs, especially
aminoglycosides, in the perilymph or the endolymph




(10ÿ5 M, 72 hr)
+poly-l-glutamate
(10ÿ5 M, 72 hr)
+poly-l-ornithine
(10ÿ7 M, 72 hr)
0.2 9227** 10926 106212 98210
0.4 8327 100212$ N.D. N.D.
0.6 5225 106210$ 103210$ 4828
1 122 99212$ 107215$ 222
N.D. = non determined
*Protection explants are pretreated with protective compound for 24 hr before exposure to neomycin.
**Results are expressed in percentage of hair cells as compared to control cultures (mean2SD, n = 12).
$Statistically significant compared with cultures exposed to neomycin alone.
Table 4. Protective eect of GSH against cisplatin-induced damage
of auditory hair cells as quantified by video image analysis*
Cisplatin (M) Untreated 2GSH (10ÿ3 M)
10ÿ6 10127 10326 **
10ÿ5 68212 10029.4$
3 10ÿ5 49.9221 94.9223.2$
10ÿ4 28211 81.6219.2$
10ÿ3 9210 10212
*P3 rat organ of Corti explants: 24 hr untreated; 48 hr cisplatin or
cisplatin + GSH.
**Results are expressed in percentage of hair cells compared with
control (mean2SD, n = 12).
$Statistically significant.
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Plate 1. Morphology of hair cell stereocilia bundles of organ of Corti explants, after 72 hr in vitro.
Treatments groups (initial 24 hr in vitro then 48 hr exposure to drugs); (A) neomycin 10ÿ3 M; (B) kana-
mycin 510ÿ2 M; (C) colistin 10ÿ4 M; (D) cisplatin 10ÿ3 M; (E) carboplatin 10ÿ4 M; and (F) chloram-
phenicol 10ÿ3 M. Phalloidin–FITC staining, Bar = 20 mm.
Plate 2. Otoprotection against neomycin ototoxicity in organ of Corti explants, after 72 hr in vitro.
Morphology of hair cell stereocilia bundles in: (A) and (C) neomycin alone for 48 hr (0.6 mM and
1 mM, respectively); (B) and (D) neomycin (0.6 mM and 1 mM, 48 hr, respectively) and poly-l-aspartic
acid (10ÿ5 M, 72 hr). Phalloidin–FITC staining, Bar = 20 mm.
Plate 3. Otoprotection against cisplatin ototoxicity in organ of Corti explants, after 72 hr in vitro.
Morphology of hair cell stereocilia bundles in: (A) glutathione (10ÿ3 M; 72 hr) alone; (B) cisplatin alone
(10ÿ4 M); (C) cisplatin (10ÿ4 M; 48 hr) and glutathione (10ÿ3 M; 72 hr). Phalloidin–FITC staining,
Bar = 20 mm.
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Plate 3.

(Tran Ba Huy et al., 1981). This could explain why
high concentrations had to be used in order to ob-
serve an ototoxic eect.
Perhaps the most interesting application of this
quantification system is its ability to screen for sub-
stances that can be used to prevent the ototoxic
side-eect of various drugs for which no alternative
exists in terms of therapeutic strategies. In this
study, we have selected as potential otoprotective
agents, substances which could be used in the clinic
and which have been found to protect other target
organs from toxicity, namely polyanions and GSH.
Indeed, systemic administration of polyamino-
acids, including poly-l-aspartic and poly-l-glutamic
acid, has been reported to provide protection against
the development of aminoglycoside-induced nephro-
toxicity in the rat, as assessed by histopathology
scoring, and to prevent functional and biochemical
lesions (Ramsammy et al., 1988). One of the objec-
tives of this study was to extend and test in the inner
ear the observation that poly-l-aspartate protects the
rat kidney against the development of aminoglyco-
sides nephrotoxicity. As can be seen in Plate 2 and
Table 3, poly-l-aspartate and poly-l-glutamate to a
large extent protect auditory hair cells against neo-
mycin-induced ototoxic damage in our in vitro
model. Polyanions, such as poly-l-aspartate or poly-
l-glutamate, may protect against aminoglycoside
ototoxicity by forming electrostatic complexes with
these drugs and inhibiting their interaction with
critical intracellular or extracellular target, as has
been shown for the protection of their nephrotoxi-
city (Ramsammy et al., 1990). Another hypothesis
could be the direct interaction of the polyanion with
the plasma membrane instead of the aminoglyco-
sides, which may constitute one of the first steps of
their toxic mechanism of action (Schacht, 1986;
Williams et al., 1987). That type of protection is also
specific for aminoglycoside antibiotics and explains
why we have not found any protection against cis-
platin ototoxicity (data not shown).
GSH is reported to diminish cisplatin-induced
neurotoxicity, and patients treated with cisplatin in
combination with GSH (doses ranging from 1.5 to
3 g/m2) exhibit a less severe neuropathic syndrome
with no negative interference of its anticancer ac-
tivity in these patients (Cavaletti et al., 1996;
Colombo et al., 1995; Di Re et al., 1993). Exper-
imental studies performed on rats have shown that
GSH provides protection against the cisplatin-
induced slowing of sensory nerve conduction vel-
ocity without interfering with the antitumour e-
cacy of this drug (Hamers et al., 1993). Our in vitro
data demonstrate that GSH also protects hair cells
from cisplatin-induced injury, although not for the
highest cisplatin concentration. However, histo-
pathological studies of deafness resulting from cis-
platin poisoning demonstrate that not only are hair
cells damaged, but that auditory neurons are also
injured (Schweitzer et al., 1986). Therefore, similar
investigations have to be undertaken to look for a
potential protective eect of GSH on auditory neur-
ons. This assumption seems reasonable since our
preliminary data suggest that a protective eect of
GSH occurs in vitro on adult rat dorsal root
ganglion neurons, and since in vivo treatment with
GSH decreases the platinum concentration in DRG
neurons (Cavaletti et al., 1992). The otoprotective
mechanism has to be elucidated, since the mechan-
ism of cisplatin ototoxicity is still unknown.
Cisplatin ototoxicity may be a result of accumu-
lation of reactive oxygen species (Rybak et al.,
1995); in that case, GSH could protect by a detoxi-
fication mechanism. A possible explanation is based
on the chemical structure of cisplatin: GSH would
form complexes with cisplatin thereby preventing
the formation of similar complexes between cispla-
tin and macromolecules of the inner ear responsible
of cisplatin ototoxicity, and such a protective mech-
anism would explain the absence of a GSH protec-
tive eect for aminoglycoside ototoxicity.
In conclusion, our results show that the potential
protective molecules tested—polyanions and GSH—
protect respectively against aminoglycosides and cis-
platin derivatives ototoxicity. To what extent these
data obtained in vitro on post-natal organ of Corti
material will be confirmed in vivo and lead to preser-
vation of hearing remains to be shown. The in vitro
screening model presented in this report allows, for
the quantification of ototoxicity, a comparison of
relative toxicity of various drugs from the same
family and the testing of otoprotective agents. This
system provides a powerful tool for the design and
evaluation of otoprotective strategies. Indeed, sys-
temic administration of poly-l-aspartate was recently
demonstrated to prevent the shift in the auditory
brain stem response threshold that occurs with gen-
tamicin treatment (Hulka et al., 1993).
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